Iowa Medicaid Pharmaceutical and Therapeutics Committee
Minutes

Date: August 20, 2026

Chairperson: Jason Kruse

Time: 9:30 a.m. to 12:07 p.m.

Location: Virtual via Microsoft Teams

Committee Members Present: Jennifer Doudna, Pharm.D., R.Ph., Jason Kruse, D.O.; Lacey Ferguson, Pharm.D.; Rachel Kinn, Pharm.D.; Tricia McComb, R.N.; Dawn Schissel, M.D.; Charles Wadle, D.O.; and Fadi Yacoub, M.D. (Vacancies July 2023: 1 Physician Assistant)

Committee Members Absent: None

Iowa DHHS Staff Present: Abby Cate, Pharm.D., Pharmacy Consultant; and Darian Forcier, Pharmacy Administrative Support.

Iowa Medicaid Staff Present: Roberta Capp, M.D., MHS; Paige Clayton, Pharm.D.; Erin Halverson, R.Ph.; Gina Kuebler, R.Ph.; and Pam Smith, R.Ph.

Managed Care Organization (MCO) Staff Present: Jordan Thoman, Wellpoint Iowa; Emily Rogers, Iowa Total Care; and Candace Jordan, Molina Healthcare of Iowa.

Jason Kruse called the meeting to order.

I. Jason Kruse asked that each committee member introduce themselves to the public. Dawn Schissel made the motion to approve the April minutes, and Fadi Yacoub seconded. The motion passed with no objections. There were no new verbal conflict of interest disclosures.

II. PDL Revision Notifications (Erin Halverson): Providers have received two notices since the last committee meeting. Due to the availability issues for Vivelle-Dot, the following PDL changes were made effective 6/12/2026: Minivelle Patch, Lyllana Patch, Estradiol (Twice Weekly) Patch and Dotti Patch to preferred. In addition, due to the availability issues for Lantus insulin pens, the following PDL changes were made effective 7/24/2026: Insulin glargine-yfgn insulin pens to preferred.

III. Drug Rebate Issues (Dr. Clayton): No issues for Drug Rebate. As discussed at previous meeting in April, the Generous Model out of White House and CMS has been announced. The 17 largest pharmaceutical manufacturers have entered into Most Favored Nation pricing agreements with the White House, and part of this is that Medicaid does get to be included in Most Favored Nation pricing. This is a voluntary model for Medicaid states in which Dr. Clayton believes Iowa (to date) has not issued their participating agreement but believes this is Iowa's intent to do so. This is a highly confidential pricing program, so Dr. Clayton is not allowed to talk to Iowa state staff about it until they are fully executed members; however she does have insight into it and it will

need to be something that is worked on during the 4th quarter meeting. Dr. Clayton mentioned there are some exciting and not so exciting things in there, but nothing bad. There will be more to discuss in future.

IV. PA Criteria/Pro-DUR Edits (Dr. Cate): PA Criteria/Pro-DUR Edits (Dr. Cate): Committee members were provided a copies of the April 2026 and May 2026 Iowa Medicaid Pharmacy Program Changes notices detailing PDL, prior authorization, and ProDUR edit changes effective June 1, 2026 and July 1, 2026, respectively, posted on the www.iowamedicaidpdl.com site on the Informational Letters page. Informational Letter dated July 8, 2026 notifying providers of Iowa Medicaid FFS pharmacy benefit administrator will transition from Change Healthcare to Optum Rx. The committee received copies of the letter sent from the DUR Commission to DHHS following their meeting on May 6, 2026, which had recommended changes to the prior authorization criteria for: Apolipoprotein C-III (ApoC-III) Inhibitors (formerly Olezarsen [Tryngolza]); Biologicals for Hidradenitis Suppurativa; Dupilumab (Dupixent); and Idiopathic Pulmonary Fibrosis and Related Lung Diseases (formerly Pirfenidone [Esbriet]/Nintedanib [Ofev]). The committee received copies of the letter sent from the DUR Commission to DHHS following their meeting on August 5, 2026, which had recommended changes to the prior authorization criteria for: Antiemetic-5HT3 Receptor Antagonists/Substance P Neurokinin Products; Cardiac Myosin Inhibitors (formerly Mavacamten [Camzyos]); Incretin Mimetics for Non-Diabetes Indications; and Setmelanotide (Imcivree); Topical Acne and Rosacea Products – removal of topical clindamycin from PA; addition of quantity limits for topical clindamycin products and removal of quantity limits for lamotrigine chewable tablets.

V. Legislation (Dr. Cate): No legislation updates.

VI. Iowa Medicaid Updates (Dr. Cate/Erin Halverson): Dr. Cate: Iowa Medicaid transitioned to Optum Rx for FFS Pharmacy Benefit administrator July 27, 2026, with no major hiccups or feedback from providers. MCO carveout is set to take place December 1, 2026 with work in progress currently.

VII. Public Comment: In addition to the written public comments provided to committee members, they heard oral public comments from the speakers shown below. They were also forwarded manufacturer comments as they were received via email prior to the meeting.

Name	**Organization / Manufacturer**	**Product**
Kevin Borth	Kura Oncology	Komzifti
Ryan Gutierrez	UCB Inc.	Kygevvi
Jennifer Schweiger	Mighty Therapeutics	Forzinity
Reanna Yenger	Johnson & Johnson	Icotyde
Anthony Staresinic	Astrazeneca	Baxfendy
Prasanna Narayanan Jeff Forshey	Rhythm Pharmaceuticals	Imcivree

Member Comments Received: None

Written Provider Comments Received: None

Written Manufacturer Comments Received: Jakafi XR

At 10:13, Fadi Yacoub motioned to go to closed session as authorized by Iowa Code Section 21.5(1)(a) of the Open Meetings Law to review or discuss economic records associated with the PDL which are required or authorized to be kept confidential. Dawn Schissel seconded, and the motion passed with unanimous roll call approval. Open session resumed at 11:00.

VIII. PDL Discussion and Deliberation (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 2) were made to maximize cost savings to the program unless otherwise noted.

1. Savella to Preferred
2. Transderm-Scop (scopolamine) to Non-Preferred
3. Scopolamine patch to Preferred
4. Imcivree (setmelanotide) to Non-Preferred with Conditions
5. Moxifloxacin tablets to Preferred

Fadi Yacoub motioned to accept the recommendations above, and Charles Wadle seconded. The decision was unanimous.

IX. Iowa Medicaid Recommended Drug List (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 3) were made to maximize cost savings to the program unless otherwise noted.

1. Pomalyst (pomalidomide) to Preferred with Conditions
2. Jakafi (ruxolitinib) to Recommended with Conditions

Fadi Yacoub motioned to accept the recommendations above, and Rachel Kinn seconded. The decision was unanimous.

X. Newly Released Drugs (Dr. Capp and Erin Halverson): All following recommendations (with numbering as provided on agenda attachment 4) were made to maximize cost savings to the program unless otherwise noted. Dr. Capp reviewed the clinical information for the new drugs, and then Erin Halverson read through the recommendations as follows:

1. Baxfendy- Recommend status on the PDL as Non-Preferred
2. Byqlovi- Recommend status on the PDL as Non-Preferred
3. Bysanti- Recommend status on the PDL as Non-Preferred Step 3
4. Cardamyst- Recommend status on the PDL as Non-Preferred
5. Ensacove- Recommend status on the RDL as Non-Recommended with Conditions (Select Oncology Agents)
6. Forzinity- Recommend status on the PDL as Non-Preferred
7. Icotyde- Recommend status on the PDL as Non-Preferred with Conditions (Biologicals for Plaque Psoriasis)

8. Idvynso- Recommend status on the RDL as Non-Recommended
9. Komzifti- Recommend status on the RDL as Non-Recommended with Conditions (Select Oncology Agents)
10. Kygevvi- Recommend status on the PDL as Non-Preferred
11. Lifyorli – Recommend status on the RDL as Non-Recommended with Conditions (Select Oncology Agents)
12. Myqorzo- Recommend status on the PDL as Non-Preferred
13. Nereus- Recommend status on the PDL as Non-Preferred with Conditions
14. Pivya- Recommend status on the PDL as Non-Preferred
15. Redemplo- Recommend status on the PDL as Non-Preferred
16. Saphnelo Auto-Injector and Prefilled Syringe- Recommend status on the PDL as Non-Preferred
17. Yuviwel- Recommend status on the PDL as Non-Preferred

Fadi Yacoub motioned to accept the recommendations above. Rachel Kinn seconded, and the decision was unanimous.

XI. Newly Released Generic Drugs and New Drug Dosage Forms/Strengths/ Combinations/BioSimilars (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	**PDL/RDL Recommendation**
Azilsartan	Non-Preferred
Beclomethasone Inhal Soln	Non-Preferred
Brivaracetam	Preferred
Dapagliflozin/Saxagliptin	Non-Preferred with Conditions
Hydrocortisone Gel 2%	Non-Preferred with Conditions
Ipratropium bromide HFA	Non-Preferred
Milnacipran	Non-Preferred
Nintedanib	Preferred with Conditions
Pomalidomide	Non-Preferred with Conditions
Rilpivirine	Non-Preferred
Tacrolimus ER Capsules	Non-Preferred with Conditions
Tapentadol	Non-Preferred with Conditions
Tapentadol ER	Non-Preferred with Conditions
Umeclidinium Ellipta	Non-Preferred

Drug Name	PDL/RDL Recommendation
Atmeksi Oral Suspension	Non-Preferred with Conditions
Avtozma	Non-Preferred with Conditions
Desmoda Oral Solution	Non-Preferred with Conditions
Enbumyst Nasal Spray	Non-Preferred
Jakafi XR	Non-Recommended with Conditions
Ontralfy Oral Solution	Non-Preferred with Conditions
Relgaabi	Non-Preferred
Sdamlo Oral Solution	Non-Preferred with Conditions
Zolymbus Ophth Gel	Non-Preferred

Dawn Schissel motioned to accept the recommendations in the tables above. Rachel Kinn seconded, and all members were in favor.

XII. Cholesterol Guidelines: Dr. Capp presented a PowerPoint outlining guidelines for cholesterol.

A motion was made by Dawn Schissel to adjourn the meeting. It was seconded by Fadi Yacoub, and all in attendance approved. The meeting adjourned at 12:07 p.m.